Title: County by county estimation of possible deaths averted, infections averted, and cost

savings of overdose prevention health centers in the United States from January 2020-June

2025.

Authors: Mike Sportiello, MD, PhD[1], Rohith Palli MD, PhD [2]

1. Emory University School of Medicine Department of Medicine. 49 Jesse Hill Dr. SE,

Suite 491, Atlanta, GA 30303. Msporti@emory.edu. Corresponding author.

2. University of Washington Department of Biomedical Informatics and Medical

Education. Box 358047. 850 Republican St. Seattle, WA 98195.

Abstract

Overdose prevention health centers (OPHCs), also known as overdose prevention

centers or safe injection facilities (SIFs), are an evidence-based strategy for people to use

drugs in an environment monitored by health care professionals with access to drug use

education, sterile supplies, and referral infrastructure to access higher levels of medical

and behavioral health resources. Though still illegal under federal law throughout the

United States, many legal or quasi-legal (including some in the United States) have

operated since the 1980s. Using CDC overdose deaths and United States Census Bureau

population data, we estimate 1,325 deaths could have been averted between 2020 and

June 2025 if 1 out of 400 injections had taken place at an OPHC. At this rate, 26 HIV

transmissions and 5,723 Hepatitis C Virus transmissions would have been averted. Over

$1.8 billion in discounted lifetime costs to treat those infections could have been saved.

This data supports OPHCs as one viable public health intervention to avert deaths and

avoid infections. Furthermore, a web application was created to assist users explore this

analysis, data visualizations, and even alter model assumptions, including variables like

what percent of injections occur at an OPHC.

Introduction

Overdose prevention health centers (OPHCs), also known as overdose prevention centers or safe injection centers, are an evidence-based strategy for people to use drugs in an environment monitored by health care professionals with access to drug use education, sterile supplies, and referral infrastructure to access higher levels of medical and behavioral health resources. Though still illegal under federal law throughout the United States, many legal or quasi-legal (including some in the United States) have operated since the 1980s (Beletsky et al., 2018). Since this time, there have been reported overdoses, but no reported deaths in this supervised health care setting, as naloxone, an opioid overdose reversal agent as well as access to respiratory support such as supplemental oxygen or bag-mask ventilation is readily available. Many other studies have focused on assessing the impact of an OPHC in their community (Irwin et al., 2016), but no study has modeled the likely impact across the country. Notably, many studies have focused on local areas in Canada and have shown reduction in deaths due to opioid overdose (Irvine et al., 2019; Pauly et al., 2020; Rammohan et al., 2024; Scheidell et al., 2024), and a recent meta-analysis demonstrated cost effectiveness of OPHC across North American cities (Behrends et al., 2024). In this manuscript, we analyze how many deaths averted, infections averted, and the cost savings accrued had the county adopted OPHCs during this time and present a web application for users to explore the data and alter model assumptions, with constraints.

Methods

Drug overdose deaths by month per county were accessed from the National Center

for Health Statistics from 2020-June 2025. Population and age data were downloaded from

the United States Census Bureau. County names were standardized. For this analysis, we

estimated 1.5% of adults were people who injected drugs (PWID) per others' work (Bradley

et al., 2023). For each PWID, we estimated 508.8 injections per year, or just under 1.5

injections per day per other's work (Bradley et al., 2023).

Deaths averted

54   Deaths averted was calculated by assuming the total number of injections stayed

55   constant. Secondly, we assumed that deaths cannot occur after an injection in the OPHC,

56   as no overdose death has ever occurred in an OPHC. The *injections that would occur at*

57   *OPHC* was calculated by modeling 0.25%, 0.5%, 0.75%, or 1% of injections taking place at

58   the OPHC. This led to the following calculation:

59
$$\frac{Injections\ that\ would\ occur\ at\ OPHC}{PWID * Injections\ per\ person} * Overdose\ deaths = Deaths\ averted$$

60   With the fraction on the left simplifying to the frequency of total injections in the OPHC,

61   multiplied by the number of deaths. If all the injections took place at the OPHC, the

62   leftmost fraction would simplify to 1 and all deaths would be averted. If none did, the whole

63   left term would simplify to 0 and no deaths would be averted.

HCV transmissions averted

Hepatitis C virus (HCV) is a highly transmissible virus in the setting of shared needle

use, leading to significant morbidity, mortality, and health expenditures. While curative

therapy now exists, it is expensive and requires weeks-long adherence, which is difficult for

many who inject drugs as they are disproportionately housing insecure and have varied of

trust in professional medical infrastructure. Similar to deaths averted, due to the supply of

sterile drug use equipment including needles and cottons, transmission of HCV has never

been documented at an OPHC. Natural incidence of HCV within PWID varies widely, with

studies with varying from 0.51 to 47 per 100 person years. For this analysis, we used a

lower-end estimate of 10 per 100 person years (Gutfraind et al., 2015), leading to the

following equation:

75
$$\frac{Injections\ that\ would\ occur\ at\ OPHC}{PWID * Injections\ per\ person} * HCV\ incidence = HCV\ transmissions\ averted$$

HIV transmissions averted

Though the vast majority of HIV is not transmitted through injection drug use, it is

still a meaningful target of HIV transmission prevention efforts. Others have calculated the

incidence of HIV transmission in groups of people who inject drugs, stratifying their use as

low, medium, and high risk depending on factors including how often they share needles

with people they know and alternatively with strangers (Jarlais et al., 2022). Using these

incidences, we calculated HIV transmissions averted with the following equations:

83
$$\frac{Injections\ that\ would\ occur\ at\ OPHC}{PWID * Injections\ per\ person} * HIV\ incidence\ [low\ risk]$$

84
$$= HIV\ transmissions\ averted$$

85
$$\frac{Injections\ that\ would\ occur\ at\ OPHC}{PWID * Injections\ per\ person} * HIV\ incidence\ [medium\ risk]$$

86
$$= HIV\ transmissions\ averted$$

$$\frac{Injections\ that\ would\ occur\ at\ OPHC}{PWID * Injections\ per\ person} * HIV\ incidence\ [high\ risk]$$

$$= HIV\ transmissions\ averted$$

Financial impact

Substantial health care dollars are spent treating preventable diseases. Infectious diseases are a particularly good target given how easily they can be prevented with appropriate education and low-cost materials. Others have estimated the discounted lifetime cost of an HIV infection to be $448,095 (after adjusting for inflation) (Schackman et al., 2015). We calculated the discounted lifetime cost of an HIV infection with the following equation:

$$\$448,095 * averted\ HIV\ transmission = Discounted\ cost\ of\ an\ averted\ HIV\ infection$$

Similar work has been done to calculate the discounted lifetime cost of HCV, calculated to $339,968 (after adjusting for inflation) (Liu et al., 2016).

$$\$339,968 * averted\ HCV\ transmission = Discounted\ cost\ of\ an\ averted\ HCV\ infection$$

Finally, we calculated the total statistical costs of the lives to those who died from overdose, using the dollar mount the Federal Emergency Medical Agency $7,500,000 uses for their calculations, giving the following equation:

$$\$7,500,000 * Averted\ deaths = Statistical\ costs\ of\ deaths\ averted$$

Web application

A web application was created using the Shiny infrastructure and written R. All code is free and open source and can be found here: https://github.com/sportiellomike/OPHC-shiny. The most up to date version of the web app itself can be found here: https://sportiellomike.shinyapps.io/OPHC-shiny/. Minimal assistance in coding was

provided by generative artificial intelligence. Anthropic's claude-3.5-sonnet model was

used. All additions provided by AI were manually checked at the time of coding for both

function and syntax. Generative AI was not utilized to create or manipulate any figure.

Results

Analytic results

Deaths averted depends on what percentage of injections occur at the OPHC (Table

1). At the low end assuming 0.25% of injections occurred at OPHCs (1 injection out of 400,

or one injection every 287 days [400/(508.8/365)]) per PWID, 1,325 deaths would have been

averted. At the higher end of 1% of injections occurring at the OPHC, over 5,300 deaths

could have been averted.

Table 1: Summary table of results

Percent injections at OPHC	0.25%	0.5%	0.75%	1%
Deaths averted	1325.12	2650.24	3975.36	5300.48
HCV averted	5722.99	11445.98	17168.98	22891.97
HIV-low averted	11.45	22.89	34.34	45.78
HIV-medium averted	26.33	52.65	78.98	105.30
HIV-high averted	32.05	64.10	96.15	128.20
Discounted lifetime cost infections	1.84E+09	3.68E+09	5.53E+09	7.37E+09
Cost of life	9.94E+09	1.99E+10	2.98E+10	3.98E+10
Total costs	1.18E+10	2.36E+10	3.53E+10	4.71E+10
Total costs (billions)	11.78	23.56	35.34	47.12

HCV infections averted range from just under 5,723 to just under 22,892 (Table 1). Dozens

of HIV transmissions could have been averted (Table 1). Tens of billions in cost would have

been averted with higher use, from relatively low rates of usage of OPHCs (Table 1).

Even if OPHCs were only instituted in the top 50 counties with the most PWID (Table

2) or the top 50 deaths per capita (Table 3), a substantial impact would be seen. A list of

these counties can be found in supplementary Tables 1 and 2 respectively.

Table 2: Results for 50 most populous counties

Percent injections at OPHC	0.25%	0.5%	0.75%	1%
Deaths averted	403.75	807.49	1211.24	1614.98
HCV averted	1738.93	3477.85	5216.78	6955.71
HIV-low averted	3.48	6.96	10.43	13.91
HIV-medium averted	8.00	16.00	24.00	32.00
HIV-high averted	9.74	19.48	29.21	38.95
Discounted lifetime cost of infections	5.60E+08	1.12E+09	1.68E+09	2.24E+09
Cost of life	3.03E+09	6.06E+09	9.08E+09	1.21E+10
Total costs	3.59E+09	7.18E+09	1.08E+10	1.44E+10
Total costs (billions)	3.59	7.18	10.76	14.35

130
131   *Table 3: Results for 50 counties with most deaths per capita*

Percent injections at OPHC	0.25%	0.5%	0.75%	1%
Deaths averted	53.28	106.56	159.84	213.12
HCV averted	83.82	167.64	251.46	335.28
HIV-low averted	0.17	0.34	0.50	0.67
HIV-medium averted	0.39	0.77	1.16	1.54
HIV-high averted	0.47	0.94	1.41	1.88
Discounted lifetime cost of infections	2.70E+07	5.40E+07	8.09E+07	1.08E+08
Cost of life	4.00E+08	7.99E+08	1.20E+09	1.60E+09
Total costs	4.27E+08	8.53E+08	1.28E+09	1.71E+09
Total costs (billions)	0.43	0.85	1.28	1.71

Web application

These results are presented here in table format, but it may be of use to users to

visualize results on a per-state or per-county basis. To assist in this process, a free and

open-source interactive web application was constructed for users to investigate individual

counties and create color-coded maps and tables with additional parameters not reported

here (discounted costs broken down between HIV and HCV, for example) specific to their

applications (Figure 1). The most up to date version can always be found at:

https://sportiellomike.shinyapps.io/OPHC-shiny/.

Figure 1: OPHC Data Explorer Web Application

Discussion

While it is difficult to estimate the rates of use of OPHCs by those injecting, this

study supplies a framework to assist in estimating their impact on deaths, infections, and

cost savings. Even at very low rates of use, assuming one out of every 400 injections occurs

at OPHCs, hundreds of deaths and thousands of HCV transmissions would have been

averted over the period studied. Dozens of HIV transmissions would have been averted.

This study also analyzes the impact on if the 50 most populous (Table 2) or the 50 counties

with the most deaths (Table 3) were to have constructed an OPHC, a potentially more

realistic and cost-effective strategy. This study makes no precise estimation on future

deaths averted, infections averted, or costs, though it is likely to be favorable as it was

during this studied time period.

Importantly, this analysis does not include secondary benefits of OPHCs like the

association of people voluntarily joining detoxification programs, methadone initiation

programs, or long-term addiction treatment initiation (Wood et al., 2007). It also doesn't

include benefits that education has such as decreasing the rates of needle sharing (Kerr et

al., 2005). Lastly, this analysis doesn't include the benefits of secondary social supports

unrelated to drug use, including housing support, food support, or other programs.

This analysis doesn't include any secondary detriments of OPHCs, though it should

be noted that most of those of concern (increase in overdoses, increase in new-onset illicit

injection drug use) have not been borne out by studies that that have actually measured

these important issues of concern. One important aspect not included in this analysis is

the cost to build and maintain these OPHCs, which would require both direct costs of

salaries of health and social workers, as well as maintaining these buildings over time.

Another drawback of this analysis is that its precision is not forward facing: we do not make

estimates on the impact of future OPHCs, just that OPHC construction would have had

large benefits in the past. New and currently ongoing interventions to reduce deaths and

infections, even without decreasing the rates of injection, would mitigate some of the

greatest benefits of OPHCs.

Another caveat of this study is the difficulty in estimating how many injections

would have occurred at the OPHCs had they been constructed. Likely, OPHC use would

vary based on a particular area's infrastructure and culture in addition to the capacity of

the OPHC itself. Which drugs used by whom in what setting with what relationship to the

healthcare and law enforcement institutions varies widely even within the same city and

sometimes the same neighborhood. A rate of 1/400 injections occurring at the OPHC, for

example, would more likely be achieved by some using the OPHC far more frequently than

that rate and most using it far less frequently than that rate. No study has used an

evidence-based estimate for likely uptake, so we present here a conservative and broad

range of 0.25%-1% of injections occurring at an OPHC.

Overall, these data support the broad construction and initiation of OPHCs as a

measure to prevent the mortality and morbidity associated with injection drug use. Our

limitations highlight the importance of more empirical work in the area to enable more even

more precise estimates.

References

Behrends, C. N., Leff, J. A., Lowry, W., Li, J. M., Onuoha, E. N., Fardone, E., Bayoumi, A. M.,
McCollister, K. E., Murphy, S. M., & Schackman, B. R. (2024). Economic Evaluations of
Establishing Opioid Overdose Prevention Centers in 12 North American Cities: A
Systematic Review. *Value Health*, *27*(5), 655–669.
https://doi.org/10.1016/j.jval.2024.02.004
Beletsky, L., Baker, P., Arredondo, J., Emuka, A., Goodman-Meza, D., Medina-Mora, M. E., Werb,
D., Davidson, P., Amon, J. J., Strathdee, S., & Magis-Rodriguez, C. (2018). The global
health and equity imperative for safe consumption facilities. *Lancet*, *392*(10147), 553–
554. https://doi.org/10.1016/S0140-6736(18)31469-7
Bradley, H., Hall, E. W., Asher, A., Furukawa, N. W., Jones, C. M., Shealey, J., Buchacz, K.,
Handanagic, S., Crepaz, N., & Rosenberg, E. S. (2023). Estimated Number of People Who
Inject Drugs in the United States. *Clin Infect Dis*, *76*(1), 96–102.
https://doi.org/10.1093/cid/ciac543
Gutfraind, A., Boodram, B., Prachand, N., Hailegiorgis, A., Dahari, H., & Major, M. E. (2015).
Agent-Based Model Forecasts Aging of the Population of People Who Inject Drugs in
Metropolitan Chicago and Changing Prevalence of Hepatitis C Infections. *PLoS One*,
10(9), e0137993. https://doi.org/10.1371/journal.pone.0137993
Irvine, M. A., Kuo, M., Buxton, J. A., Balshaw, R., Otterstatter, M., Macdougall, L., Milloy, M. J.,
Bharmal, A., Henry, B., Tyndall, M., Coombs, D., & Gilbert, M. (2019). Modelling the
combined impact of interventions in averting deaths during a synthetic-opioid overdose
epidemic. *Addiction*, *114*(9), 1602–1613. https://doi.org/10.1111/add.14664
Irwin, A., Jozaghi, A., Bluthenthal, R. N., & Kral, A. H. (2016). A Cost-Benefit Analysis of a
Potential Supervised Injection Facility in San Francisco, California, USA. *Journal of Drug*
Issues, *47*(2). https://doi.org/https://doi.org/10.1177/0022042616679829
Jarlais, D. D., Bobashev, G., Feelemyer, J., & McKnight, C. (2022). Modeling HIV transmission
among persons who inject drugs (PWID) at the "End of the HIV Epidemic" and during the
COVID-19 pandemic. *Drug Alcohol Depend*, *238*, 109573.
https://doi.org/10.1016/j.drugalcdep.2022.109573
Kerr, T., Tyndall, M., Li, K., Montaner, J., & Wood, E. (2005). Safer injection facility use and
syringe sharing in injection drug users. *Lancet*, *366*(9482), 316–318.
https://doi.org/10.1016/S0140-6736(05)66475-6
Liu, S., Barnett, P. G., Holodniy, M., Lo, J., Joyce, V. R., Gidwani, R., Asch, S. M., Owens, D. K., &
Goldhaber-Fiebert, J. D. (2016). Cost-Effectiveness of Treatments for Genotype 1
Hepatitis C Virus Infection in non-VA and VA Populations. *MDM Policy Pract*, *1*(1).
https://doi.org/10.1177/2381468316671946
Pauly, B., Wallace, B., Pagan, F., Phillips, J., Wilson, M., Hobbs, H., & Connolly, J. (2020). Impact
of overdose prevention sites during a public health emergency in Victoria, Canada. *PLoS*
One, *15*(5), e0229208. https://doi.org/10.1371/journal.pone.0229208
Rammohan, I., Gaines, T., Scheim, A., Bayoumi, A., & Werb, D. (2024). Overdose mortality
incidence and supervised consumption services in Toronto, Canada: an ecological study
and spatial analysis. *Lancet Public Health*, *9*(2), e79–e87. https://doi.org/10.1016/S2468-
2667(23)00300-6

Schackman, B. R., Fleishman, J. A., Su, A. E., Berkowitz, B. K., Moore, R. D., Walensky, R. P.,
229   Becker, J. E., Voss, C., Paltiel, A. D., Weinstein, M. C., Freedberg, K. A., Gebo, K. A., &
230   Losina, E. (2015). The lifetime medical cost savings from preventing HIV in the United
231   States. *Med Care*, *53*(4), 293–301. https://doi.org/10.1097/MLR.0000000000000308
232   Scheidell, J. D., Townsend, T. N., Zhou, Q., Manandhar-Sasaki, P., Rodriguez-Santana, R., Jenkins,
233   M., Buchelli, M., Charles, D. L., Frechette, J. M., Su, J. I., & Braithwaite, R. S. (2024).
234   Reducing overdose deaths among persons with opioid use disorder in connecticut. *Harm
235   Reduct J*, *21*(1), 103. https://doi.org/10.1186/s12954-024-01026-6
236   Wood, E., Tyndall, M. W., Zhang, R., Montaner, J. S., & Kerr, T. (2007). Rate of detoxification
237   service use and its impact among a cohort of supervised injecting facility users.
238   *Addiction*, *102*(6), 916–919. https://doi.org/10.1111/j.1360-0443.2007.01818.x
239

Counties with highest number of PWID
California-Los Angeles County
Illinois-Cook County
Texas-Harris County
Arizona-Maricopa County
California-San Diego County
California-Orange County
Florida-Miami-Dade County
New York-Kings County
Texas-Dallas County
New York-Queens County
California-Riverside County
Washington-King County
Nevada-Clark County
California-San Bernardino County
Texas-Tarrant County
Florida-Broward County
Texas-Bexar County
California-Santa Clara County
New York-New York County
Michigan-Wayne County
California-Alameda County
Massachusetts-Middlesex County
Pennsylvania-Philadelphia County
Florida-Palm Beach County
California-Sacramento County
New York-Suffolk County
Florida-Hillsborough County
Florida-Orange County
New York-Nassau County
New York-Bronx County
Texas-Travis County
Ohio-Franklin County
Michigan-Oakland County
Pennsylvania-Allegheny County
Minnesota-Hennepin County
Ohio-Cuyahoga County
California-Contra Costa County
North Carolina-Wake County

Virginia-Fairfax County
Utah-Salt Lake County
North Carolina-Mecklenburg County
Georgia-Fulton County
Arizona-Pima County
Texas-Collin County
Maryland-Montgomery County
Florida-Pinellas County
Hawaii-Honolulu County
New York-Westchester County
Florida-Duval County
Missouri-St. Louis County

242   *Supplementary table 1: Counties with highest number of PWID*

Counties with highest deaths per capita
Texas-Borden County
New Mexico-Rio Arriba County
Kentucky-Lee County
Nebraska-Logan County
Texas-Kent County
New Mexico-Taos County
Alaska-Lake and Peninsula County
California-Lake County
Kentucky-Powell County
West Virginia-Logan County
Maryland-Baltimore (city) County
West Virginia-Cabell County
Kansas-Greeley County
Kentucky-Estill County
West Virginia-Lincoln County
Kentucky-Knott County
Kentucky-Breathitt County
West Virginia-Mercer County
California-Del Norte County
Kentucky-Boyd County
Arizona-La Paz County
West Virginia-Mingo County

Texas-Karnes County
Tennessee-Roane County
Texas-Irion County
Louisiana-Washington County
Washington-Okanogan County
Alaska-Anchorage County
Kentucky-Clay County
Tennessee-Morgan County
Tennessee-DeKalb County
Washington-Grays Harbor County
West Virginia-McDowell County
Alabama-Walker County
Virginia-Buchanan County
Kentucky-Rockcastle County
Missouri-St. Louis (city) County
Texas-Dickens County
North Dakota-Golden Valley County
California-Butte County
California-Alpine County
Tennessee-Cocke County
New Mexico-Santa Fe County
Nebraska-Garden County
Washington-Spokane County
Kentucky-Harlan County
Colorado-Cheyenne County
Pennsylvania-Philadelphia County
Tennessee-Campbell County
Utah-Piute County

245   *Supplementary table 2: Counties with highest deaths per capita*